Onco Actu du 30 septembre 2016

	1. Biologie
Flicking the switch on cancer’s immaturity [Cancer Research UK] “Cancer cells naturally change as the tumour grows, which can affect the cells’ ability to divide,” says Scaffidi. “Some of this is genetic, with the cells acquiring new genetic faults. But we’ve now shown that there is an additional layer of diversity which is non-genetic and, importantly, reversible.”
Biologists plan scoring system for antibodies [Nature] Manufacturers and users will rank reagents to improve the reliability of research.
	2.6 Etiologie - Environnement
Europe's food safety watchdog says to release studies on weed-killer glyphosate [Reuters] "Transparency and openness are essential values for EFSA because they strengthen confidence in science," EFSA said in a statement. "The information will be shared with a group of MEPs following a public access to document request".
	3. Prévention
Men with a high genetic chance of bowel cancer could have lower risk with healthy lifestyle [Cancer Research UK] The study used mathematical models that included 37 different factors that could put people at risk of cancer to calculate how likely it was for a man to be diagnosed with bowel cancer over the next 25 years.
	4. Dépistage, diagnostic et pronostic
How this ICR PhD student is helping bring personalised medicine to children with cancer [The Institute of Cancer Research] After two years working on the project with the ICR, Elisa revealed her ‘NGS paediatric multi-gene panel for children with solid tumours’.
	4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
US FDA approves TAGRISSO® (osimertinib) blood-based T790M companion diagnostic test [AstraZeneca] The companion diagnostic for TAGRISSO is the only FDA-approved and clinically validated companion diagnostic test that uses either tissue or a blood sample to confirm the presence of a T790M mutation in patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC), who have progressed on or after an EGFR tyrosine kinase inhibitor (TKI) medicine.
	5. Traitements
Ovarian removal to prevent ovarian cancer should not be an option for most premenopausal women, Mayo research finds [Mayo Clinic] The study showed that women under 46 who had both ovaries removed experienced a significantly elevated risk of multiple chronic health conditions that included depression, hyperlipidemia, cardiac arrhythmias, coronary artery disease, arthritis, asthma, chronic obstructive pulmonary disease and osteoporosis.
	5.12.1 Immunothérapies - partenariats
Boehringer Ingelheim and SARAH CANNON Research Institute launch strategic collaboration to develop novel immune-oncology therapies [Boehringer Ingelheim] Joint clinical development will study the combination of two checkpoint inhibitors from Boehringer Ingelheim’s growing immune-oncology pipeline.
	5.12.2 Immunothérapies - CAR-T
Will Programmable Immune “Cellbots” Be the Next Weapon Against Cancer? [Xconomy] Lim calls programmable T cells “cellbots.” Several devices used to simulate cells in communication sit on his office table like high-tech tea candles, blinking at each other. Lim, wearing a collared sweater, shorts, and worn leather sandals, fiddles with them as he talks.
UCSF scientist rolls out a new blueprint for programming T cells, the 2.0 way [EndPoints] In what amounts to developing living micro devices, Lim believes the technology can be used to program T cells to produce checkpoint inhibitors, bispecific antibodies and customizable cytokines, among other things. And it can also all be integrated into CAR-T with a suicide switch.
Cell Design Labs, Little Partner Of Kite Pharma, Pushes T-Cell Engineering Frontier [Forbes] It’s still a long way from claiming victory, but a group of scientists from the University of California San Francisco are reporting today in the journal Cell that they have a way to engineer T-cells that can orchestrate a custom immune response to the tumor microenvironment.
	5.2.1 Pharma - Partenariats
Genentech, South Korean pharma in up to $910M+ RAF inhibitor deal [FierceBiotech] The candidate at the center of the deal is HM95573, which is a selective pan-RAF inhibitor, which was developed to target B-RAFmut and/or N-RASmut/C-RAF driven solid tumors.
Genentech snares a PhI RAF inhibitor from Hanmi in $910M deal [EndPoints] For Hanmi, this is the latest in a string of high-profile pacts with some of the world’s biggest drug developers. The third largest pharma company in Korea, Hanmi has been ramping up an ambitious R&D effort that covers a variety of diseases.
	5.3 Traitements - FDA, EMA,...
Are Golden Tickets That Speed Drugs Through FDA Worthwhile? [NPR] Sarepta Therapeutics was awarded a voucher for a fast-track drug review by the Food and Drug Administration when the company's medicine for Duchenne muscular dystropy was approved Sept. 19. Now Sarepta is looking to sell the voucher to the highest bidder.
New judicial decisions at odds with EMA’s efforts to allow access to documents on medicines [EMA] EMA appeals interim measures.
European regulators appeal rulings that prevent release of drug data [STAT] In the latest dust up, the European Medicines Agency is appealing two different rulings by the General Court of the European Union that prevent it from releasing data to third parties.
	5.4 Traitements - Economie
The Cancer Drugs Fund is producing dangerous, bad data: randomise everyone, everywhere! [Bad Science] The Cancer Drugs Fund is being marketed as a way to generate new knowledge: but in reality, the data that will be collected is weak, observational evidence, riven through with confounders.
	5.6 ESMO
Bayer to Showcase Latest Oncology Research at ESMO 2016 Congress [Bayer] Includes a late-breaking oral presentation of results from the Phase III RESORCE trial evaluating regorafenib in unresectable hepatocellular carcinoma (HCC) / Additional presentations include early pipeline data on Bayer’s investigational oral pan-fibroblast growth factor receptor (FGFR) inhibitor, and further data on radium-223 dichloride in metastatic castration-resistant prostate cancer (mCRPC).
ESMO 2016 Press Release: Ki67 May Help Avoid Sentinel Lymph Node Biopsy in Some Patients [ESMO] Analysis of data from 1,785 patients treated for breast cancer (T1-T2, N0-N1) at the National Cancer Institute of Milan showed higher Ki67 values were significantly associated with larger tumour size and increased likelihood of axillary lymph node metastases in patients aged 50 years or older, regardless of hormone receptor or HER2 status.
Genomic Health Reinforces Global Leadership in Genomic-based Diagnostics with Presentation of Nine Personalized Medicine Studies Conducted in Six Countries at ESMO 2016 Congress [PR Newswire] Broad Range of Presentations Includes Oncotype SEQ™ Liquid Biopsy Analytical Validation, New Outcomes Data in Invasive Breast Cancer and Studies in Node-positive Disease.
	5.9.1 ASTRO
Cardiac risk a factor when considering hormonal therapy for prostate cancer [Yale] In a recent study, a Yale Cancer Center team determined that men who received hormonal therapy for prostate cancer had a net harm if they had a prior history of a heart attack. The findings were presented September 28 at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting in Boston.
	6. Lutte contre les cancers
When a Nobel Prize brings a shower of hype: the roller coaster ride of RNAi [STAT] The path from a brilliant lab discovery to an actual medication is long and winding — and sometimes, high expectations can backfire. Take the roller coaster ride of RNA interference, a Nobel-winning technology that received heaps of accolades and billions of dollars in funding, only to stumble badly when the science didn’t deliver actual drugs – at least, not fast enough for investors.
	6.10.1 Politiques (USA)
Senate effort to increase access to experimental drugs is blocked [STAT] But whether the Right to Try movement can succeed is uncertain. As we have noted previously, there are numerous questions about the extent to which the laws — which have been drafted by the Goldwater Institute, a Libertarian think tank, and introduced in more than a dozen other states — can accomplish their goals.
	6.11 Patients
Doctors: Breaking Bad News to Patients [NY Times] My patient was in his mid-30s and had mild intellectual impairment, with an I.Q. that probably fell shy of three digits. When I first met him and told him about his leukemia diagnosis, he was living with his mother and employed at a factory doing piecework.
	6.7.3 DMP
Doctors: E-health records raise costs, don’t help patient outcomes [Computer World] Three out of four U.S. physicians believe that electronic healthcare records (EHRs) increase practice costs -- outweighing any efficiency savings -- and seven out of 10 think they reduce productivity, according to a new survey.
By The Numbers: Our Progress In Digitizing Health Care [Health Affairs Blog] Collaboration with states and the private sector is vital to this work. We have been working diligently with stakeholders, who we invited to sign a pledge indicating their commitment to advancing toward an interoperable community of health.
	6.9 Controverses
How Trump was named ‘Grand Benefactor’ for a Dana-Farber gala without donating a penny [STAT] The relationship between Trump and Dana-Farber opens a window into the world of high-dollar philanthropy, where galas with celebrity guests attract wealthy donors who hop from party to party on the social circuit.